Successful Treatment of Delusional Disorder of the Somatic Type or “Delusional Parasitosis” with Olanzapine

 

 Buy Article Permissions and Reprints

Introduction

Delusional disorder of the somatic type is a rare psychiatric condition. It has also been called chronic tactile hallucinosis (where the primary problem is considered to be tactile hallucinations), delusional parasitosis or monosymptomatic hypochondriacal psychosis [2] [9] [12]. The patients have a false and fixed belief that they are infested with parasites [12]. DSM-IV describes delusional disorder as having non-bizarre delusions (i.e., involving situations that occur in real life, such as being followed, poisoned, infected, loved at a distance, or deceived by spouse or lover, or having a disease) for at least one month. Criterion A for schizophrenia has never been met although tactile and olfactory hallucinations may be present in delusional disorder if they are related to the delusional theme. The delusions cannot be due to the effects of substance abuse or a general medical condition. Subtypes are erotomanic, grandiose, jealous, persecutory, somatic, mixed and unspecified. When the same delusion develops in another individual, often a spouse, the disorder is called folie a deux [1].

Since the 1970s the treatment of choice has been the typical antipsychotic pimozide. There have been several case reports and studies that support this choice [5] [10] [11].

Recently there have been case reports stating the value of the atypical antypsychotics risperidone, olanzapine, and quetiapine [3] [4] [6] [7] [8] [11].

Lepping et al. tried to evaluate the usefulness of typical and atypical antipsychotics in delusional disorder, somatic type by conducting a systematic review. They concluded that both typical and atypical antipsychotics were effective in the majority, but that remission rates did not differ significantly. They suggest more rigorous studies to evaluate the effectiveness and to compare typical and atypical antipsychotics directly [7].

References

• 1 American Psychiatric Association .Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. 4th edn., Text revision. Washington, DC: American Psychiatric Association 2000
• 2 Bers N, Conrad K. Die chroniche taktile halluzinose.  Fortschr Neurol Psychiatr. 1954;  22 254-270
  PubMedGoogle Scholar
• 3 Leon OA De, Furmaga KM, Canterbury AL, Bailey LG. Risperidone in the treatment of delusions of infestation.  Int J Psychiatry Med. 1997;  27 403-409
  PubMedGoogle Scholar
• 4 Freudenmann RW, Schonfeldt-Lecuona C. Delusional parasitosis: treatment with atypical antipsychotics.  Ann Acad Med Singapore. 2005;  34 141-142
  PubMedGoogle Scholar
• 5 Johnson GC, Anton RF. Pimozide in delusions of parasitosis.  J Clin Psychiatry. 1983;  44 233
  PubMedGoogle Scholar
• 6 Koo J, Lee CS. Delusions of parasitosis. A dermatologist's guide to diagnosis and treatment.  Am J Clin Dermatol. 2001;  2 285-290
  CrossrefPubMedGoogle Scholar
• 7 Lepping P, Russel I, Freudenmann RW. Antipsychotic treatment of primary delusional parasitosis: systematic review.  Br J Psychiatry. 2007;  191 198-205
  CrossrefPubMedGoogle Scholar
• 8 Meehan WJ, Badreshia S, Mackley CL. Successful treatment of delusions of parasitosis with olanzapine.  Arch Dermatol. 2006;  142 352-355
  CrossrefPubMedGoogle Scholar
• 9 Munro A. Monosymptomatic hypochondriacal psychosis manifesting as delusions of parasitosis.  Arch Dermatol. 1978;  114 940-943
  CrossrefPubMedGoogle Scholar
• 10 Riding J, Munro A. Pimozide in the treatment of monosymptomatic hypochondriacal psychosis.  Acta Psychiatr Scand. 1975;  52 23-30
  PubMedGoogle Scholar
• 11 Wenning MT. et al . Atypical antipsychotics in the treatment of delusional parasitosisis.  Ann Clin Psychiatry. 2003;  15 233-239
  CrossrefPubMedGoogle Scholar
• 12 Wilson FC, Uslan DZ. Delusional parasitosis.  Mayo Clin Proc. 2004;  79 1470
  PubMedGoogle Scholar

Correspondence

Dr. A. Bosmans

UVC Brugmann

4 Van Gehughtenplein

1020 Brussel

Belgium

Email: aadbosmans@hotmail.com